三药联合治疗急性心肌梗死并发恶性心律失常的疗效观察

目的探讨倍他乐克、可达龙、门冬氨酸钾镁联合用药治疗急性心肌梗死并发恶性心律失常的疗效。方法选取我院2009年6月至2011年6月收治的急性心肌梗死并发恶性心律失常患者90例,按随机数字表法分为对照组和观察组,每组45例。对照组给予急性心肌梗死常规治疗和倍他乐克治疗;观察组在此基础上给予门冬氨酸钾镁和可达龙治疗。比较两组疗效以及心源性事件发生率和病死率。结果观察组总有效率为95.6%(43/45),对照组为77.8%(35/45),两组相比差异有统计学意义(P<0.05);观察组心源性事件发生率显著少于对照组(P<0.05),但比较病死率结果无统计学意义(P>0.05)。结论倍他乐克、可达龙、门冬氨酸钾镁联合治疗急性心肌梗死并发恶性心律失常能显著提高疗效,降低心源性事件的发生率,值得临床推广应用。

Clinical Observation of the Therapeutic Effect of Three-drug Combination for Acute Myocardial Infarction with Malignant Arrhythmia

Objective To investigate the efficacy of betaloc,cordarone,and potassium magnesium aspartate combination therapy for 45 cases of acute myocardial infarction(AMI)with malignant arrhythmia.Methods A total of 90 cases of AMI with malignant arrhythmia patients admitted to our hospital from June 2009 to June 2011 were selected,according to random number table,they were divided into control group and observation group,45 cases each.The control group was given conventional treatment of AMI and betaloc;the observation group was given potassium-magnesium aspartate and cordarone on the basis of control group medication.The efficacy,cardiogenic event incidence and mortality of the two groups were compared.Results The total effective rate of the observation group was 95.6%(43/45),the control group was 77.8%(35/45),the difference had statistical significance(P<0.05).Cardiogenic events incidence of the observation group was significantly less than the control group(P<0.05),and the mortality had no significant difference between the two groups(P>0.05).Conclusion Combination therapy of AMI with malignant arrhythmia by betaloc,cordarone,potassium magnesium aspartate can significantly improve clinical efficacy and reduce the incidence of cardiogenic events,thus is worthy of clinical application.